Universal reference book for medicines
Product name: LORAGEXAL ® (LORAHEXAL)

Active substance: loratadine

Type: The blocker of histamine H 1 -receptors.
Anti-allergic drug
Manufacturer: HEXAL (Germany) manufactured by SALUTAS PHARMA (Germany)
Composition, form of production and packaging
?
Tablets are white, oval, with a risk and engraved "LT" and "10" on one side.
1 tab.

loratadine 10 mg

Excipients: lactose monohydrate, corn starch, silicon dioxide colloidal anhydrous, magnesium stearate.

7 pcs.
- blisters (1) - packs of cardboard.
7 pcs.
- blisters (2) - packs of cardboard.
7 pcs.
- blisters (3) - packs of cardboard.
7 pcs.
- blisters (5) - packs of cardboard.
10 pieces.
- blisters (1) - packs of cardboard.
10 pieces.
- blisters (2) - packs of cardboard.
10 pieces.
- blisters (3) - packs of cardboard.
10 pieces.
- blisters (5) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.

The product description was approved by the manufacturer for the 2009 print edition.

PHARMACHOLOGIC EFFECT

Lorahexal is an antihistamine drug, a blocker of histamine H 1 -receptors.
Does not have a central and anticholinergic effect. Lorahexal does not cause drowsiness and does not affect psychomotor functions, attention, performance, mental abilities.
PHARMACOKINETICS

When ingestion the drug is absorbed well from the digestive tract.
Absorption of the drug is not dependent on food intake.
The drug begins 30 minutes after taking 1 tablet and lasts for 24 hours. Loratadine is metabolized in the liver with the formation of an active metabolite of descarbotoxyloratadine.
C max loratadine and its active metabolite in blood plasma are achieved through 1.3-2.5 h after taking 1 tablet of Lorahexal.
INDICATIONS

For adults and children over 2 years of age:

- seasonal and all-the-year-round allergic rhinitis, conjunctivitis, hay fever, urticaria, incl.
chronic idiopathic urticaria;
- Quincke's edema;

- pseudoallergic reactions;

- itching dermatoses;

- Allergic reactions to insect bites.

DOSING MODE

It is applied inside.

Adults and children over 12 years of age - 10 mg (1 tab.) 1 time / day.
The daily dose is 10 mg.
Children from 2 to 12 years - 5 mg (1/2 tab /) 1 time / day.
The daily dose is 5 mg.
Children with a body weight of more than 30 kg - 10 mg (1 tab /) 1 time / day.
The daily dose is 10 mg.
SIDE EFFECT

Rarely: dry mouth, nausea, vomiting, gastritis, impaired liver function, headache, fatigue, excitability (in children), dizziness, cough, tachycardia, allergic reactions.

In some cases: alopecia.

CONTRAINDICATIONS

- Hypersensitivity to any of the components of the drug.

PREGNANCY AND LACTATION

It should be refrained from using Lorahexal during pregnancy and lactation.

APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS

Patients with violations of the liver Lauragexal should be prescribed in an initial dose of 5 mg / day in connection with a possible violation of the clearance of loratadine.

APPLICATION FOR CHILDREN

It is not recommended for children under 2 years old.

SPECIAL INSTRUCTIONS

Patients with violations of the liver Lauragexal should be prescribed in an initial dose of 5 mg / day in connection with a possible violation of the clearance of loratadine.

It is not recommended for children under 2 years old.

OVERDOSE

Symptoms: drowsiness, tachycardia, headache.

Treatment: take measures to remove the drug from the digestive tract and reduce absorption.

DRUG INTERACTION

When using loratadine in therapeutic doses, its interaction with alcohol was not revealed.

Erythromycin, cimetidine, ketoconazole when combined with loratadine increase the concentration of loratadine in the blood plasma, without causing clinical manifestations and without affecting the ECG.

TERMS OF RELEASE FROM PHARMACY

The drug is approved for use as a means of OTC.

TERMS AND CONDITIONS OF STORAGE

Store at a temperature not higher than 25 ° C in a place inaccessible to children.
Shelf life - 3 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!